en
Scientific article
Open access
English

Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir

Publication date2021
Abstract

Glecaprevir/pibrentasvir is approved for treating chronic hepatitis C virus (HCV) genotypes (GT) 1-6. We evaluated real-world effectiveness, safety, and patient-reported outcomes of glecaprevir/pibrentasvir in underserved patient populations, focusing on persons who use drugs infected with HCV.

Citation (ISO format)
AGHEMO, Alessio et al. Real-world outcomes in historically underserved patients with chronic hepatitis C infection treated with Glecaprevir/Pibrentasvir. In: Infectious Diseases and Therapy, 2021. doi: 10.1007/s40121-021-00455-1
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal2193-6382
147views
60downloads

Technical informations

Creation06/17/2021 3:04:00 PM
First validation06/17/2021 3:04:00 PM
Update time03/16/2023 12:48:49 AM
Status update03/16/2023 12:48:47 AM
Last indexation02/12/2024 12:07:15 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack